Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

GSK Seeking Up to $2B Bolt-on Acquisitions in India

publication date: Oct 4, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
GlaxoSmithKline is looking to complete “smaller” acquisition targets in India in the $500 million to $2 billion range, according to the company’s CEO Andrew Witty. He characterized these transactions as bolt-on additions rather than transformative ones. GSK does not need a large acquisition, he said, because the company already has a well-established presence in India with a recognizable brand name. His comments would seem to apply equally to China, where GSK has been involved in several "smaller" M&A transactions. More details....

Stock Symbol: (NYSE: GSK)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners